Scott Smith
@Acuta Capital Partners, Llc
Latest period2024 - Q3ReportedManaged Assets$123.464MTotal holdings41
Assets growth rate3.99%Assets growth rate (2-Q avg)-9.44%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Acuta Capital Partners, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 41 positions.
Assets under management
The assets under management (AUM) of Acuta Capital Partners, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 123.464M in assets, with a quarterly growth rate of 3.99% and a 2-quarter average growth rate of -9.44%. The portfolio is managed by Scott Smith, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
PCVXVaxcyte Inc
| 12.54% | $15.472M 135,400 shares@ $114.27 avg price | Increased 22.65% |
TRMLTourmaline Bio Inc
| 6.92% | $8.538M 332,095 shares@ $25.71 avg price | Increased 23.18% |
INSMInsmed Inc
| 6.36% | $7.848M 107,500 shares@ $73.0 avg price | Increased 49.1% |
ACLXArcellx Inc
| 4.21% | $5.186M 62,100 shares@ $83.51 avg price | Increased 47.16% |
MREOMereo Biopharma Group Plc
| 4.2% | $5.181M 1.261M shares@ $4.11 avg price | Increased 86.22% |
TERNTerns Pharmaceuticals Inc
| 3.29% | $4.062M 487,000 shares@ $8.34 avg price | Increased 31.88% |
KURAKura Oncology Inc. Common Stock
| 3.12% | $3.849M 197,000 shares@ $19.54 avg price | Increased 20.86% |
ARGXArgenx Se
| 2.6% | $3.198M 5,900 shares@ $542.08 avg price | Increased 47.5% |
HLXBHelix Acquisition Corp Ii
| 1.54% | $1.891M 180,945 shares@ $10.45 avg price | Increased 1.75% |
TRVITrevi Therapeutics Inc
| 0.79% | $970,270 290,500 shares@ $3.34 avg price | Increased 11.74% |